关键和慢性护理中的右心衰竭:当前的概念,挑战和机械支持策略
Debora Emanuela Torre1, Carmelo Pirri2
1Department of Cardiac Anesthesia and Intensive Care Unit, Cardiac Surgery, Ospedale dell'Angelo, 30174 Venice Mestre, Italy.
Medical sciences (Basel, Switzerland)
|October 24, 2025
概括
右心力衰竭 (RHF) 是重症患者的严重疾病. 最近在诊断和机械循环支持方面的进展为管理RHF提供了新的希望.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 心血管外科心血管外科
背景情况:
- 右心力衰竭 (RHF) 在重症和慢性患者中是未被认可和破坏性的.
- 它通常会使心脏手术,肺栓塞,晚期心力衰竭,败血症和LVAD植入复杂化.
- 临床决策受到复杂的病理生理学,诊断局限性和分散的治疗环境的阻碍.
研究的目的:
- 综合当前关于RHF基础的证据.
- 划分急性和慢性形式,并比较诊断工具和MCS策略.
- 支持早期识别,量身定制的管理,以及针对RHF的创新疗法.
主要方法:
- 对RHF的现有证据的审查.
- 对解剖学,生理学和分子方面的分析.
- 对诊断工具和机械循环支持 (MCS) 策略的比较分析.
主要成果:
- 血液动力学表型,心声学和生物标志物的进展有助于评估RHF.
- 发展MCS,包括RVAD,V-A ECMO,Impella RP和BiPella,扩大了管理选择.
- 将机械学见解与临床框架相结合至关重要.
结论:
- 对于高风险RHF患者来说,早期识别和量身定制的管理至关重要.
- 先进的诊断和MCS策略正在扩大治疗武器库.
- 对创新治疗方法的进一步研究是有必要的.
相关概念视频
Heart Failure V: Medical Management
215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
Heart Failure VI: Adjunct Therapies
252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252
Heart Failure VII: Nursing Interventions
413
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
413
Heart Failure IV: Classification and Diagnostic Evaluation
317
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
317
Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
Cardiomyopathy II: Dilated Cardiomyopathy
464
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
464


